Search

Purpose Methods Results Conclusion To assess the predictive performance of DIGIROP‐v1.0 models in identifying treatment‐requiring ROP among infants undergoing ROP screening at a tertiary neonatal intensive care unit in Greece.Retrospective cohort analysis of 640 consecutive screened preterm infants with gestational age (GA) 240/7 to 306/7 weeks and known ROP outcome in the 2nd Neonatology Department of Aristotle University of Thessaloniki (2009–2021). The primary outcome was the development of type 1 ROP according to the Early Treatment of ROP criteria or treatment based on the ophthalmologist's judgement. Sensitivity, specificity, area under the curve (AUC) with corresponding 95% confidence intervals (CI) and calibration plots for the DIGIROP‐v1.0 models were displayed.The DIGIROP‐Birth‐v1.0 model correctly identified 35/43 treated infants (sensitivity 81.4% [95% CI, 66.6%–91.6%], specificity 61.5% [95% CI, 57.4%–65.4%], AUC 0.82 [95% CI, 0.75–0.90]). During the postnatal weeks 6–14 the sensitivity of the DIGIROP‐Screen‐v1.0 model ranged from 82.6% to 100%. Eleven infants, all with severe comorbidities, that is, congenital malformation(s), syndrome(s), hydrocephalus or history of intestinal surgery, that were treated, were missed by the model, but met criteria for screening according to DIGIROP‐v1.0 models' recommendations, and to our unit's routine standards.The DIGIROP‐v1.0 models resulted in lower sensitivity and higher specificity in this Greek cohort compared with the Swedish development group. Despite higher GA and BW, infants in our cohort had higher incidence of treated ROP than in Sweden, resulting in an under‐estimation of their risk for treatment‐requiring ROP. Further validation of the DIGIROP‐v2.0 models and potential adjusting are recommended to maximize generalizability in populations with different characteristics. [ABSTRACT FROM AUTHOR]

Purpose: The purpose of the study was to investigate the association of platelet parameters and postnatal weight gain with treatment‐requiring ROP (TR‐ROP). Methods: In this retrospective matched case–control study, infants with TR‐ROP were individually matched, according to gestational age and birth weight, with one or two untreated infants who developed no or spontaneously regressed ROP. Longitudinal data on platelet count (PLT), mean platelet volume (MPV), daily weight and platelet transfusions were collected. Platelet mass index (PMI) and weight standard deviation score (WSDS) were also calculated. Conditional logistic regression analysis was performed to adjust for matching. Results: Fourteen cases, presenting type I ROP, and 25 matched controls were included. The odds of developing TR‐ROP decreased as PLT increased during 31st week of postmenstrual age (PMA) or during 1st and 2nd week of postnatal age (PNA). The odds of developing TR‐ROP were 16.7 times higher in infants receiving at least one platelet transfusion compared with those who were not transfused. The odds of developing TR‐ROP increased by 31.2% as the mean volume of platelet transfusion per infant increased by 1 ml. The odds of developing TR‐ROP decreased as PMI increased during 1st week PNA, and as weight and WSDS increased during 4th–6th week PNA. Analysis of MPV, number of thrombopenic episodes per infant, number of platelet transfusions per infant and days with WSDS < −2 showed no association with TR‐ROP. Conclusion: To our knowledge, this is the first study ascertaining an association of platelet transfusions with type I ROP. Prospective cohort studies are required to confirm our findings. [ABSTRACT FROM AUTHOR]